Literature DB >> 22754070

Antitrypanosomal activity of Senna villosa in infected BALB/c mice with Trypanosoma cruzi during the sub acute phase of infection.

Matilde Jimenez-Coello1, Eugenia Guzman-Marin, Salud Perez-Gutierrez, Glendy Marilu Polanco-Hernandez, Karla Yolanda Acosta-Viana.   

Abstract

Antitrypanosomal activity of chloroform extract of Senna villosa leaves was evaluated in the sub acute phase of mice infected with Trypanosoma cruzi. Oral doses of 3.3, 6.6 and 13.2 µg/g were tested during 15 days on infected mice BALB/c, beginning treatment 40 days after infection to evaluate specifically the antitrypanosomal activity over the amastigote form of the parasite. Two different amount of parasites (100 and 500) were inoculated to 25 mice for each doses tested. At the end of the assay the animals were sacrificed and cardiac and skeletal tissue sections were stained with hematoxylin-eosin (HE) for identification and quantification of amastigote nest. In mice infected with 100 parasites, a significant reduction in the number of amastigote nest was observed in cardiac tissue of treated animals at all doses evaluated (p<0.05). An important reduction of amastigote nest was also observed in treated animals and infected with 500 parasites in comparison with no treated mice or treated with allopurinol.

Entities:  

Keywords:  Antiprotozoal; Senna villosa; Trypanosoma cruzi; amastigote

Mesh:

Substances:

Year:  2011        PMID: 22754070      PMCID: PMC3252712          DOI: 10.4314/ajtcam.v8i5S.21

Source DB:  PubMed          Journal:  Afr J Tradit Complement Altern Med        ISSN: 2505-0044


  22 in total

Review 1.  Parasitological cure of Chagas disease: is it possible? Is it relevant?

Authors:  J A Urbina
Journal:  Mem Inst Oswaldo Cruz       Date:  1999       Impact factor: 2.743

Review 2.  A critical review on Chagas disease chemotherapy.

Authors:  José Rodriques Coura; Solange L de Castro
Journal:  Mem Inst Oswaldo Cruz       Date:  2002-01       Impact factor: 2.743

Review 3.  Natural products as antiparasitic drugs.

Authors:  O Kayser; A F Kiderlen; S L Croft
Journal:  Parasitol Res       Date:  2003-02-20       Impact factor: 2.289

4.  Anti-trypanosomal activity of (8-hydroxymethylen)-trieicosanyl acetate against infective forms of Trypanosoma cruzi.

Authors:  Matilde Jimenez-Coello; Karla Y Acosta-Viana; Eugenia Guzman-Marin; Cuahutemoc Perez Gonzalez; Maria Salud Perez Gutierrez
Journal:  Pharm Biol       Date:  2010-06       Impact factor: 3.503

Review 5.  Plant metabolites active against Trypanosoma cruzi.

Authors:  S Sepúlveda-Boza; B K Cassels
Journal:  Planta Med       Date:  1996-04       Impact factor: 3.352

6.  [Myocardial cell response to Trypanosoma cruzi infection].

Authors:  M Postan; M R Arnaiz; L E Fichera
Journal:  Medicina (B Aires)       Date:  1999       Impact factor: 0.653

7.  A study of the trypanocidal and analgesic properties from Lychnophora granmongolense (Duarte) Semir & Leitão Filho.

Authors:  C F Grael; W Vichnewski; G E Souza; J L Lopes; S Albuquerque; W R Cunha
Journal:  Phytother Res       Date:  2000-05       Impact factor: 5.878

8.  Inhibition of Trypanosoma cruzi growth in mammalian cells by purine and pyrimidine analogs.

Authors:  J Nakajima-Shimada; Y Hirota; T Aoki
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

9.  Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice.

Authors:  Eric Dumonteil; Javier Escobedo-Ortegon; Norma Reyes-Rodriguez; Arletty Arjona-Torres; Maria Jesus Ramirez-Sierra
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 10.  Chagas disease: role of parasite genetic variation in pathogenesis.

Authors:  Andra M Macedo; Riva P Oliveira; Srgio D J Pena
Journal:  Expert Rev Mol Med       Date:  2002-03-05       Impact factor: 5.600

View more
  1 in total

1.  Synergistic Effect of Lupenone and Caryophyllene Oxide against Trypanosoma cruzi.

Authors:  Glendy Polanco-Hernández; Fabiola Escalante-Erosa; Karlina García-Sosa; María E Rosado; Eugenia Guzmán-Marín; Karla Y Acosta-Viana; Alberto Giménez-Turba; Efraín Salamanca; Luis M Peña-Rodríguez
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-20       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.